An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Millions of Americans in the early stages of chronic kidney disease (CKD) are at an increased risk of having atrial fibrillation (AF) - a major risk factor for stroke - according to new research by investigators at Wake Forest University Baptist Medical Center.
Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.
IntriCon Corporation, a designer, developer, manufacturer and distributor of body-worn medical devices, today announced financial results for its second quarter ended June 30, 2010.
BIOTRONIK, the pioneer of wireless remote monitoring technologies and leading manufacturer of implantable cardiac devices, announced today that the final results of the landmark TRUST Trial (Lumax-T/Lumos-T Safely RedUceS RouTine Office Device Follow-Up) have been published in the July 27, 2010 issue of Circulation. BIOTRONIK Home Monitoring is the industry's first and most advanced wireless remote monitoring system for patients with cardiac devices.
The pioneering research, using detailed computer models, could help save lives through preventative treatment of those most at risk from a form of heart rhythm disorder called sick sinus syndrome.
Merck and Cardiome Pharma Corp. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing approval for BRINAVESS® (vernakalant), an investigational intravenous (IV) formulation for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.
St. Jude Medical, Inc., a global medical device company, today announced Japanese Ministry of Health, Labour and Welfare approval and reimbursement approval of its Therapy Cool Path Ablation Catheter. This marks the company's first entry into the irrigated catheter ablation market in Japan.
nContact Surgical, Inc. reports with interest today the results of a physician-initiated study of the Convergent Procedure that, for the first time, measured the progress of persistent atrial fibrillation (AF) patients at one-year and six-month intervals. Results of the study, which were presented at the 2010 International Society of Minimally Invasive Cardiac Surgeons meeting in Berlin, Germany, indicated that after one year 80% of patients were in sinus rhythm and off anti-arrhythmic medication as a result of the closed chest, multi-disciplinary AF procedure.
Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced today that the U.S. Food and Drug Administration (FDA) has cleared for marketing the CARTOXPRESS™ Software Module and the LASSO® NAV Circular Mapping Catheter for use with the CARTO® XP Mapping System.
Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.
AGA Medical Holdings, Inc. today announced first patient enrollment in the feasibility phase of the prospective, multicenter, randomized AMPLATZER® Cardiac Plug clinical trial. Dr. William Nicholson, an interventional cardiologist and structural heart specialist at York Hospital in Pennsylvania, enrolled the first patient.
Relypsa, Inc., today announced the initiation of patient enrollment in a Phase 2, open-label titration clinical study of the company's lead drug candidate, RLY5016, in heart failure patients with chronic kidney disease. RLY5016 is a novel non-absorbed oral potassium binder intended to prevent and treat hyperkalemia, a serious condition characterized by elevated serum potassium levels.
Vascular surgery may be accompanied by cardiovascular complications, like ventricular tachyarrhythmia. Though, these arrhythmias initially might be asymptomatic, they can lead to increased risk for late sudden cardiac death after surgery. Researchers from the Netherlands believe that cardiac high-risk patients with new-onset perioperative VT might benefit from preemptive cardioverter defibrillator implantation in addition to optimal focused medical therapy.
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced Phase 1 data for its novel heart failure Positron Emission Tomography (PET) imaging agent, LMI 1195, which is in development for the evaluation of patients at risk of heart failure or sudden cardiac death.
Watermark Medical, Inc., a privately-held medical products and services company currently servicing the sleep-disordered breathing market, today announced the completion of a $15 million equity investment from CA Technologies. This equity investment in Watermark Medical represents CA Technologies' entry into the emerging Software-as-a-Service -based healthcare cloud market.
Arrhythmia Alliance, the Heart Rhythm Charity, announced today the results of a survey conducted in Europe that showed a large number of respondents ignore basic measures to check for potential cardiac arrhythmias, or heart rhythm disorders. To raise awareness of the importance of pulse checking and to inform people about how to take their pulse, the Arrhythmia Alliance will open 2010 World Heart Rhythm Week (7-13 June) with the launch of the global awareness campaign 'Know Your Pulse'.
Focusing on helping clinicians improve experiences for their patients, GE Healthcare is highlighting an innovative portfolio of molecular imaging technologies and agents at the 57th annual meeting of the Society of Nuclear Medicine, June 5-9, in Salt Lake City.
A new treatment known as a visually-guided laser-balloon catheter successfully interrupted abnormal electrical pulses in patients and pigs with intermittent, irregular heartbeats, in a study reported in Circulation: Arrhythmia and Electrophysiology, a journal of the American Heart Association.
PulseOximetersDIRECT.com, the leading online retailer of portable Pulse Oximeter products introduces today the new, affordable $39 FDA approved Landon Medical LM-800 Finger Pulse Oximeter for home use.
In non-sleepy patients with obstructive sleep apnea, treatment with continuous positive airway pressure can reduce the incidence of cardiovascular events and hypertension, according to researchers from Spain.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.